PharmacoEconomics - Open
2017 - 2025
Current editor(s): Timothy Wrightson and Christopher Carswell From Springer Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing (). Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.
Volume 9, issue 4, 2025
- Using Generative Artificial Intelligence in Health Economics and Outcomes Research: A Primer on Techniques and Breakthroughs pp. 501-517

- Tim Reason, Sven Klijn, Will Rawlinson, Emma Benbow, Julia Langham, Siguroli Teitsson, Kasper Johannesen and Bill Malcolm
- Measuring the Socioeconomic Impact of Cancer: A Systematic Review and Standardized Assessment of Patient-Reported Outcomes (PRO) Instruments pp. 519-539

- Phu Duy Pham, Jasper Ubels, Rachel Eckford and Michael Schlander
- A Systematic Literature Review of the Economic and Healthcare Resource Utilization Burden of Relapsed/Refractory Follicular Lymphoma pp. 541-570

- Bijal Shah, Mei Xue, Wesley Furnback, Erlene K. Seymour, Jin Kim, Po-Ya Chuang, Madeline Dec and Keri Yang
- Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in High-Risk Older Adults in Japan pp. 571-584

- Hardik Goswami, Atsushi Tajima, Taizo Matsuki and Amy Puenpatom
- Cost-Effectiveness of Ultrasound Renal Denervation for Resistant Hypertension in Belgium, France and The Netherlands pp. 585-595

- Rod S. Taylor, Kaylie Metcalfe, Antoine Cremer, Sofie Brouwers, Joost Daemen, Sam Carter, Kieran Murphy, Marie-Claude Morice, Isabelle Durand-Zaleski, Linh Ngo, Michel Azizi and Ajay J. Kirtane
- Indirect Treatment Comparisons in EUnetHTA Relative Effectiveness Assessments: Learnings and Recommendations for the Implementation of EU Joint Clinical Assessments pp. 597-609

- Sophie Beekhuizen, Menglu Che, Loraine Monfort, Mahmoud Hashim, Ali Azough, Nicole Kubitz, Adrian Griffin and Martin Price
- Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified? pp. 611-626

- Waranya Rattanavipapong, Thunyarat Anothaisintawee, Wanrudee Isaranuwatchai, Duangrurdee Wattanasirichaigoon, Thipwimol Tim-Aroon, Khunton Wichajarn, Achara Sathienkijkanchai, Pimlak Charoenkwan, Kanya Suphapeetiporn, Chanchai Traivaree, Chulaluck Kuptanon and Yot Teerawattananon
- Optimizing Diabetic Retinopathy Screening at Primary Health Centres in India: A Cost-Effectiveness Analysis pp. 627-638

- Neha Purohit, Parul Chawla Gupta, Sandeep Buttan, Akashdeep Singh Chauhan, Ranjan Kumar Choudhury, Vishali Gupta, Atul Kotwal and Shankar Prinja
- Effects of Generic Entry on Market Shares and Prices of Originator Drugs: Evidence from Chinese Pharmaceutical Market pp. 639-648

- Weimiao Li, Xiaoyu Li, Yaoguang He, Luwen Shi and Jing Chen
- Cost-Effectiveness of Using Conditional Economic Incentives to Improve Pre-exposure Prophylaxis Adherence Among Male Sex Workers pp. 649-659

- Carlos Chivardi, Alejandro Zamudio-Sosa, Marta Wilson-Barthes, Fernando Alarid-Escudero, Monica Gandhi, Kenneth H. Mayer, Don Operario and Omar Galárraga
- Healthcare Expenditure Trajectories in the Last 5 Years of Life: A Retrospective Cohort Study of Decedents with Advanced Cancer and End-Stage Organ Diseases pp. 661-670

- Sheryl Hui-Xian Ng, Palvinder Kaur, Laurence Lean Chin Tan, Mervyn Yong Hwang Koh, Andy Hau Yan Ho, Allyn Hum and Woan Shin Tan
- Cost–Benefit Analysis of the Enhancing Men’s Awareness of Testicular diseases (E-MAT) Feasibility Trial: A Virtual Reality Experience to Increase Testicular Knowledge and Self-Examination among Male Athletes pp. 671-682

- Aileen Murphy, Ann Kirby, Federica Blasio, Megan McCarthy, Frances Shiely, Josephine Hegarty, Martin P. Davoren, Janas M. Harrington, Gillian W. Shorter, David Murphy, Billy O’Mahony, Eoghan Cooke, Michael J. Rovito, Steve Robertson, Serena FitzGerald, Alan O. Connor, Mícheál O. Riordan and Mohamad M. Saab
- Patient Validation of Estimation of Health Utility Values in Alopecia Areata pp. 683-692

- Caleb Dixon, Thomas Price, Elin Gruffydd, Andrew Lloyd and Ernest H. Law
- Economic Evaluation of Patiromer in Patients with Concomitant Heart Failure and Chronic Kidney Disease in Italy pp. 693-706

- M. Senni, E. Paoletti, Ewa Stawowczyk, M. Hale and A. Ramirez Arellano
Volume 9, issue 3, 2025
- From Vision to Reality: The EU’s Pharmaceutical Reforms and the Path to Improved Access pp. 331-339

- Caitlin Main, Cathrin Schäfer and Panos Kanavos
- Do We Understand Unmet Need? A Proposal to Use Length-Of-Life Equivalent (LOLE) as a Patient-Centric Measure of Unmet Need pp. 341-350

- Kevin Marsh, Robert F. Reynolds, Linda Nelsen, Stephen Watt, Omar A. Escontrías and Brett Hauber
- Cost Effectiveness of Left Ventricular Assist Devices (LVADs) as Destination Therapy: A Systematic Review pp. 351-363

- Tuba Saygın Avşar, Louise Jackson, Pelham Barton, Sophie Beese, Okeke Ogwulu Chidubem, Sern Lim, David Quinn, Malcolm J. Price and David J. Moore
- Economic Burden of Acute Myeloid Leukemia in European Union: Results from a Systematic Review of Literature pp. 365-378

- Alisha Saeed, Zermina Tasleem, Sohail Ayaz Muhammad, Anees Rehman, Shahid Shah, Qurratul Ain Jamil, Hajra Siddiqui, Hidayah Karuniawati and Saleh Karamah Al-Tamimi
- Cost-Effectiveness Analysis of Daridorexant for the Pharmacological Treatment of Chronic Insomnia Disorder in Adults pp. 379-397

- Andrew H. Briggs, François-Xavier Chalet, Jacie Cooper, Peter Graham, Stephen Palmer, Paul Miller, Andrew Walker, Berkeley Greenwood and Charles M. Morin
- COVID-19 Vaccine Preferences in China: A Comparison of Discrete Choice Experiment and Profile Case Best–Worst Scaling pp. 399-413

- Enxue Chang, Yanni Jia, Xiaoying Zhu, Lunan Wang, Ying Yan, Kejun Liu and Weidong Huang
- Pricing for Multi-Indication Drugs in the Italian Regulatory Context pp. 415-422

- Maria Grazia Ursino, Annalisa Milano, Filippo Viti Angelis, Eva Alessi and Francesco Trotta
- Burden of Disease and Cost of Illness of Triple-Negative Breast Cancer in Portugal pp. 423-431

- Joana Silva, Gabriela Sousa, Luís Costa, Margarida Brito, Sónia Oliveira, Bernardo Rodrigues, João Ferreira, Margarida Borges and Luís Miguel
- Predicting Danish EQ-5D-5L Utilities Based on United Kingdom EQ-5D-3L Utilities for Use in Health Economic Models pp. 433-443

- Einar B. Torkilseng, Nathan Clarke, Liza Sopina, Lars Oddershede, Rasmus Trap Wolf, Rachael Lawrance, Andrew Trigg, Bryan Bennett and James W. Shaw
- Costs and Complications of Respiratory Syncytial Virus and Acute Respiratory Infections in the Adult Population: Analysis of a German Claims Database pp. 445-459

- Pavo Marijic, Roman Kliemt, Martin Krammer, Nikolaus Kolb, Theo Last, Andreas Ambrosch, Santiago Ewig, Rembert Koczulla, Jörg Schelling, Claus Vogelmeier, Maria Waize, Manuela Stierl, Maria João Fonseca, Sara Pedron and Alen Marijam
- So Many Choices, So Little Value: Potential Savings from Selecting Cost-Effective Proton Pump Inhibitors pp. 461-469

- Hye-Young Kwon
- Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer pp. 471-485

- Leila-Sophie Otten, Alessandra I. G. Buma, Berber Piet, Rob Heine, Michel M. Heuvel and Valesca P. Retèl
- Semaglutide 2.4 mg versus Liraglutide 3 mg for the Treatment of Obesity in Greece: A Short-Term Cost-Effectiveness Analysis pp. 487-497

- Panagiotis Papantoniou and Nikolaos Maniadakis
- Publisher Correction: Pricing for Multi-Indication Drugs in the Italian Regulatory Context pp. 499-499

- Maria Grazia Ursino, Annalisa Milano, Filippo Viti Angelis, Eva Alessi and Francesco Trotta
Volume 9, issue 2, 2025
- Incorporating Resource Constraints in Health Economic Evaluations: Overview and Methodological Considerations pp. 161-178

- Praveen Thokala, Henrique Duarte, Stuart Wright, Don Husereau, Isabelle Durand-Zaleski, Peter Lindgren, Roelien Postema, Gerardo Machnicki and Louis Garrison
- Economic Burden of Haemophilia from a Societal Perspective: A Scoping Review pp. 179-205

- Amr A. El-Sayed and Nancy S. Bolous
- What Does Pharmaceutical 3D Printing Cost? A Framework and Case Study with Hydrocortisone for Adrenal Insufficiency pp. 207-215

- Sejad Ayyoubi, Liesbeth Ruijgrok, Hugo Kuy, Renske Ham and Frederick Thielen
- Economic Evaluation of Total Knee Replacement Compared with Non-Surgical Management for Knee Osteoarthritis in India pp. 217-229

- Amatullah Sana Qadeer, Ananda Meher, Jennifer Rachel, Winnie Paulson, Abhilash Patra, Naline Gandhi, Nirupama Ay, Lipika Nanda, Sarit Kumar Rout and Ambarish Dutta
- The Association between COVID-19 Status and Economic Costs in the Early Stages of the COVID-19 Pandemic: Evidence from a UK Symptom Surveillance Digital Survey pp. 231-245

- Sung Wook Kim, Caterina Alacevich, Catia Nicodemo, Raphael Wittenberg, Simon Lusignan and Stavros Petrou
- Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year Data pp. 247-257

- Alison D. Griffiths, Robert O. Young, Yong Yuan, Mohammad A. Chaudhary, Adam Lee, Jason Gordon and Philip McEwan
- Health-Economic Modelling of Improved Behavior in Insulin Injection Technique in Belgium pp. 259-270

- Kristof Theys, Sofie Vermander, Lieven Annemans, Christophe De Block, Michel P. Hermans, Imke Matthys, Frank Nobels, Trung Nguyen, Vanessa Preumont, Katerina Zakrzewska and Frank Vanderdonck
- Comparing Different Implementation Strategies for Collaborative Dementia Care Management in Terms of Patients’ Characteristics, Unmet Needs, and the Impact on Quality of Life and Costs in Germany pp. 271-282

- Moritz Platen, Wolfgang Hoffmann and Bernhard Michalowsky
- Burden of Disease of Breast Cancer in Italy: A Real-World Data Analysis pp. 283-290

- F. S. Mennini, A. Marcellusi, P. Sciattella, M. Scortichini, Angela Ragonese, F. Cattel, R. D’Antona, L. Mastro, S. Gori, G. Perrone, R. Migliorini and M. Trabucco Aurilio
- Clinical Complications and Healthcare Resource Utilization Associated with Conventional Management of Sickle Cell Disease with Recurrent Vaso-occlusive Crises and Transfusion-Dependent β-Thalassemia in Germany pp. 291-300

- Chuka Udeze, Nanxin Li, Colin Kunzweiler, Jessica Baldwin, Petra Tuzin, Sebastian Dietmar Zingel, Céline Vetter, Silvia Dombrowski, Elena Georgiadou-Schmidt, Aranzazu Alba and Roland Meisel
- Cost-Utility Analysis of LifeVest® in Post-Myocardial Infarction Patients at Risk of Sudden Cardiac Death in England pp. 301-312

- Vasileios Kontogiannis, Farai Goromonzi, Brigitte Both, Frank Semrau, Michael Branagan-Harris, Jowan Atkinson, Paul R. Roberts and Mehdi Javanbakht
- From Clinical to Non-clinical Outcomes in the Treatment of HIV: An Economic and Organizational Impact Assessment pp. 313-326

- Lucrezia Ferrario, Barbara Menzaghi, Giuliano Rizzardini, Alessandro Roccia, Elisabetta Garagiola, Daniele Bellavia, Fabrizio Schettini and Emanuela Foglia
- Correction: From Clinical to Non-clinical Outcomes in the Treatment of HIV: An Economic and Organizational Impact Assessment pp. 327-327

- Lucrezia Ferrario, Barbara Menzaghi, Giuliano Rizzardini, Alessandro Roccia, Elisabetta Garagiola, Daniele Bellavia, Fabrizio Schettini and Emanuela Foglia
- Correction: Mapping the World Health Organization Disability Assessment Schedule (WHODAS 2.0) onto SF-6D Using Swedish General Population Data pp. 329-329

- Anna Philipson, Lars Hagberg, Liselotte Hermansson, Jan Karlsson, Emma Ohlsson-Nevo and Linda Ryen
Volume 9, issue 1, 2025
- Costs of Illness for Huntington’s Disease: A Systematic Review pp. 5-13

- Divya Patil, Emily F. Gorman and T. Joseph Mattingly
- Health Economic Evaluation of Antimicrobial Stewardship, Procalcitonin Testing, and Rapid Blood Culture Identification in Sepsis Care: A 90-Day Model-Based, Cost-Utility Analysis pp. 15-25

- Wendy I. Sligl, Charles Yan, Jeff Round, Xiaoming Wang, Justin Z. Chen, Cheyanne Boehm, Karen Fong, Katelynn Crick, Míriam Garrido Clua, Cassidy Codan, Tanis C. Dingle, Connie Prosser, Guanmin Chen, Alena Tse-Chang, Daniel Garros, David Zygun, Dawn Opgenorth, John M. Conly, Christopher J. Doig, Vincent I. Lau and Sean M. Bagshaw
- Digital Versus Paper-Based Consent from the UK NHS Perspective: A Micro-costing Analysis pp. 27-39

- Rachel Houten, Mohammad Iqbal Hussain, Antony P. Martin, Nick Ainsworth, Claudia Lameirinhas, Alexander W. Coombs, Simon Toh, Christopher Rao and Edward St John
- Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study pp. 41-56

- Aren Fischer, Stephen Mac, Erica Stivelman Freiman, John K. Marshall, Kim Rand and Juan M. Ramos-Goñi
- Healthcare Resource Utilization and Associated Costs During the First 5 Years After Diagnosis and at the End of Life: A Nationwide Cohort Study of Patients with Multiple Myeloma in Finland pp. 57-68

- Mikko Kosunen, Jarno Ruotsalainen, Alvar Kallio, Roope Metsä, Paavo Raittinen, Leena Lehmus, Maarit J. Korhonen and Timo Purmonen
- Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand pp. 69-81

- Tanawan Kongmalai, Juthamas Prawjaeng, Phorntida Hadnorntun, Pattara Leelahavarong, Usa Chaikledkaew, Ammarin Thakkinstian and Varalak Srinonprasert
- Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis pp. 83-92

- Zheng-Yi Zhou, Mark E. Bensink, Nisha C. Hazra, Chunyi Xu, Bruce Hendry, Claire C. Sharpe and Mo Zhou
- Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA pp. 93-101

- Dong-Won Kang, Patricio B. Lynn, Li Wang, Shouhao Zhou and Chan Shen
- CMS’s Drug Price Negotiation Program 2023 Patient-Focused Listening Sessions: A Descriptive Analysis of Speaker Remarks pp. 103-113

- Julie A. Patterson, Tyler D. Wagner, Rayan K. Salih, Gabri’el D. Shabazz and Jonathan D. Campbell
- Mortality, Clinical Complications, and Healthcare Resource Utilization Associated with Managing Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-occlusive Crises in Italy pp. 115-124

- Chuka Udeze, Melania Dovizio, Chiara Veronesi, Luca Degli Esposti, Nanxin Li, Thi Xuan Mai Patricia Dang and Gian Luca Forni
- Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line Treatment pp. 125-136

- Yan Chen, Ella X. Du, Manasvi Sundar, Keith A. Betts, Xin Yin, Samantha Eiffert, Karen Beauchamp, Andrew Delgado and Lisa Rosenblatt
- Cost-Effectiveness of Three Different New-Generation Drug-Eluting Stents in the Randomised BIO-RESORT Trial at 3 Years pp. 137-145

- Eline H. Ploumen, Martijn J. Oude Wolcherink, Rosaly A. Buiten, Tineke H. Pinxterhuis, Carine J. M. Doggen, Carl E. Schotborgh, Peter W. Danse, Martijn Scholte, K. Gert Houwelingen, Paolo Zocca, Xavier G. L. V. Pouwels and Clemens Birgelen
- Integrating Multi-Cancer Early Detection (MCED) Tests with Standard Cancer Screening: System Dynamics Model Development and Feasibility Testing pp. 147-160

- Mussab Fagery, Hadi A. Khorshidi, Stephen Q. Wong, Özge Karanfil, Jon Emery and Maarten J. IJzerman
| |